Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.

Hybridoma. 1999 Apr;18(2):149-57. Unique Identifier : AIDSLINE MED/99306682
Ota A; Tanaka-Taya K; Ueda S; Department of Neurovirology, Research Institute for Microbial; Diseases, Osaka University, Suita City, Japan.

Abstract: Strong antibody responses are often seen in human immunodeficiency virus type 1 (HIV-1) carriers, but it is not known whether these antibodies are effective in the inhibition of disease progression. In this study, we examined antigenic epitopes for anti-HIV-1 p17 antibody (p17 Ab) in an HIV-1 carrier's serum, and found that the residues of amino acid numbers 1 to 12 (P1-12), 12 to 29 (P12-29) and 30 to 52 (P30-52) of p17 were highly recognized in the serum. Our examination of purified antibodies from the patient using the p17-derivative-peptide-immunoaffinity columns showed that the reactivity of anti-p30-52 Ab (p30-52Ab) was high for p30-52 and the naive protein, p17. In addition, this P30-52Ab cross-reacted with the third variable region of the envelope glycoprotein (Env V3). To confirm this cross-reactivity, we immunized mice with P30-52, and established a monoclonal antibody (MAb), 8H10. We found that 8H10 was also reactive to Env V3. It is unclear whether this cross-reactivity of P30-52 Ab can function as the inhibitor of HIV-1, but these results will be of help in clarifying the interaction of Env protein with HIV-1 gag polyprotein and the relationship of the decline of the p17 antibody titer with the disease progression in HIV-1 carriers.

Keywords: JOURNAL ARTICLE Amino Acid Sequence Animal Antibodies, Monoclonal/IMMUNOLOGY Antibody Affinity Antibody Specificity Biosensing Techniques Carrier State Cross Reactions Enzyme-Linked Immunosorbent Assay Epitopes Female Gene Products, gag/*IMMUNOLOGY Human HIV Antibodies/*IMMUNOLOGY HIV Antigens/*IMMUNOLOGY HIV Envelope Protein gp120/*IMMUNOLOGY HIV Infections/*IMMUNOLOGY HIV-1/*IMMUNOLOGY Mice Mice, Inbred BALB C Molecular Sequence Data Peptide Fragments/*IMMUNOLOGY Recombinant Proteins/IMMUNOLOGY
991030
A99A0886

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .